154 related articles for article (PubMed ID: 26935861)
21. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
[TBL] [Abstract][Full Text] [Related]
23. Presence of EGF growth factor ligands and their effects on cultured rat conjunctival goblet cell proliferation.
Gu J; Chen L; Shatos MA; Rios JD; Gulati A; Hodges RR; Dartt DA
Exp Eye Res; 2008 Feb; 86(2):322-34. PubMed ID: 18155194
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling of ErbB receptors and ligands in human meningiomas.
Laurendeau I; Ferrer M; Garrido D; D'Haene N; Ciavarelli P; Basso A; Vidaud M; Bieche I; Salmon I; Szijan I
Cancer Invest; 2009 Jul; 27(6):691-8. PubMed ID: 19440932
[TBL] [Abstract][Full Text] [Related]
25. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression.
Sundaresan S; Roberts PE; King KL; Sliwkowski MX; Mather JP
Endocrinology; 1998 Dec; 139(12):4756-64. PubMed ID: 9832411
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
27. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
[TBL] [Abstract][Full Text] [Related]
28. Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies.
Takahashi N; Iwasa S; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita N; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Br J Cancer; 2016 Apr; 114(9):1003-11. PubMed ID: 27002940
[TBL] [Abstract][Full Text] [Related]
29. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H; Eshima K
Eur J Cancer; 2011 Sep; 47(13):1946-54. PubMed ID: 21531130
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.
Andersson U; Guo D; Malmer B; Bergenheim AT; Brännström T; Hedman H; Henriksson R
Acta Neuropathol; 2004 Aug; 108(2):135-42. PubMed ID: 15148612
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
[TBL] [Abstract][Full Text] [Related]
32. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical localization of epidermal growth factor system in the lung of the Japanese quail (Coturnix coturnix japonica) during the post-hatching period.
Alan E; Lİman N; Sağsöz H
Microsc Res Tech; 2015 Sep; 78(9):807-22. PubMed ID: 26179370
[TBL] [Abstract][Full Text] [Related]
34. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
[TBL] [Abstract][Full Text] [Related]
35. Expression of the epidermal growth factor system in human middle ear cholesteatoma.
Thorup MB; Munk M; Poulsen SS; Gaihede M; Nexo E; Sorensen BS; Ovesen T
Acta Otolaryngol; 2014 Feb; 134(2):124-34. PubMed ID: 24256036
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2.
Maurer CA; Friess H; Kretschmann B; Zimmermann A; Stauffer A; Baer HU; Korc M; Büchler MW
Hum Pathol; 1998 Aug; 29(8):771-7. PubMed ID: 9712416
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
38. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
39. Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction.
Borer JG; Park JM; Atala A; Nguyen HT; Adam RM; Retik AB; Freeman MR
Lab Invest; 1999 Nov; 79(11):1335-45. PubMed ID: 10576204
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
